Bulletin
Investor Alert

New York Markets Open in:

SIGA Technologies Inc.

NAS: SIGA

GO
/marketstate/country/us

After Hours

 --Quotes are delayed by 20 min

Jan 27, 2022, 4:30 p.m.

/zigman2/quotes/201166334/composite

$

6.25

Change

+0.04 +0.64%

Volume

Volume 2,772

Quotes are delayed by 20 min

/zigman2/quotes/201166334/composite

Previous close

$ 6.31

$ 6.21

Change

-0.10 -1.58%

Day low

Day high

$6.17

$6.41

Open

52 week low

52 week high

$5.66

$9.82

Open

Company Description

SIGA Technologies, Inc. is a commercial-stage pharmaceutical company which engages in the development and commercialization of solutions for serious unmet medical needs and biothreats. The company develops therapeutic solutions for lethal pathogens including smallpox, Ebola, dengue, Lassa fever, and...

SIGA Technologies, Inc. is a commercial-stage pharmaceutical company which engages in the development and commercialization of solutions for serious unmet medical needs and biothreats. The company develops therapeutic solutions for lethal pathogens including smallpox, Ebola, dengue, Lassa fever, and other dangerous viruses. It offers an orally administered antiviral drug that targets orthopoxviruses under the TPOXX brand. The company was founded by Steven Oliveira on December 28, 1995 and is headquartered in New York, NY.

Valuation

P/E Current

8.90

P/E Ratio (with extraordinary items)

29.56

P/E Ratio (without extraordinary items)

10.25

Price to Sales Ratio

4.62

Price to Book Ratio

4.32

Price to Cash Flow Ratio

8.07

Enterprise Value to EBITDA

4.14

Enterprise Value to Sales

6.28

Total Debt to Enterprise Value

0.01

Efficiency

Revenue/Employee

2,975,222.00

Income Per Employee

1,341,476.00

Receivables Turnover

33.29

Total Asset Turnover

0.71

Liquidity

Current Ratio

13.70

Quick Ratio

11.77

Cash Ratio

11.25

Profitability

Gross Margin

88.16

Operating Margin

67.62

Pretax Margin

58.83

Net Margin

45.09

Return on Assets

32.22

Return on Equity

49.51

Return on Total Capital

54.03

Return on Invested Capital

48.60

Capital Structure

Total Debt to Total Equity

1.81

Total Debt to Total Capital

1.78

Total Debt to Total Assets

1.56

Long-Term Debt to Equity

1.46

Long-Term Debt to Total Capital

1.44

Officers and Executives

Name Age Officer Since Title
Dr. Phillip Louis Gomez 52 2016 Chief Executive Officer & Director
Ms. Tove C. Bolken - 1998 Senior VP-Operations & Chief Supply Chain Officer
Mr. Daniel J. Luckshire 48 2011 Secretary, Chief Financial & Accounting Officer
Mr. Herb Vloedman - 2009 Chief Information Officer
Dr. Dennis E. Hruby 67 1996 Vice President-Research

Insider Actions

– Purchase – Sale 1 – Number of Transactions
Date Name Shares Transaction Value
12/09/2021 James J. Antal
Director
30,000   Disposition at $7.82 per share. 234,600
07/31/2021 Daniel J. Luckshire
Executive VP & CFO
13,902   Derivative/Non-derivative trans. at $6.37 per share. 88,555
07/31/2021 Daniel J. Luckshire
Executive VP & CFO
26,667   Derivative/Non-derivative trans. at $0 per share. 0
06/15/2021 Eric A. Rose
Director
15,000   Derivative/Non-derivative trans. at $0 per share. 0
06/15/2021 Thomas E. Constance
Director
15,000   Derivative/Non-derivative trans. at $0 per share. 0
06/15/2021 Joseph W. Marshall
Director
15,000   Derivative/Non-derivative trans. at $0 per share. 0
06/15/2021 James J. Antal
Director
15,000   Derivative/Non-derivative trans. at $0 per share. 0
06/15/2021 Michael C. Plansky
Director
15,000   Derivative/Non-derivative trans. at $0 per share. 0
06/15/2021 Julie M. Kane
Director
15,000   Derivative/Non-derivative trans. at $0 per share. 0
06/15/2021 Jaymie A. Durnan
Director
15,000   Derivative/Non-derivative trans. at $0 per share. 0
08/27/2020 James J. Antal
Director
30,000   Disposition at $7.1 per share. 213,000
07/31/2020 Daniel J. Luckshire
Executive VP & CFO
13,005   Derivative/Non-derivative trans. at $6.42 per share. 83,492
07/31/2020 Robin E. Abrams
General Counsel and CAO
14,138   Derivative/Non-derivative trans. at $6.42 per share. 90,765
07/31/2020 Daniel J. Luckshire
Executive VP & CFO
26,667   Derivative/Non-derivative trans. at $0 per share. 0
07/31/2020 Robin E. Abrams
General Counsel and CAO
26,667   Derivative/Non-derivative trans. at $0 per share. 0
05/21/2020 Eric A. Rose
Director
15,000   Derivative/Non-derivative trans. at $0 per share. 0
05/21/2020 Thomas E. Constance
Director
15,000   Derivative/Non-derivative trans. at $0 per share. 0
05/21/2020 Paul G. Savas
Director
15,000   Derivative/Non-derivative trans. at $0 per share. 0
05/21/2020 Joseph W. Marshall
Director
15,000   Derivative/Non-derivative trans. at $0 per share. 0
05/21/2020 Jeffrey B. Kindler
Director
15,000   Derivative/Non-derivative trans. at $0 per share. 0
05/21/2020 James J. Antal
Director
15,000   Derivative/Non-derivative trans. at $0 per share. 0
05/21/2020 Michael C. Plansky
Director
15,000   Derivative/Non-derivative trans. at $0 per share. 0
05/21/2020 Julie M. Kane
Director
15,000   Derivative/Non-derivative trans. at $0 per share. 0
12/09/2019 Phillip Louis Gomez
Chief Executive Officer; Director
10,000   Acquisition at $4.42 per share. 44,200
12/09/2019 Paul G. Savas
Director
20,000   Acquisition at $4.37 per share. 87,400
12/09/2019 Daniel J. Luckshire
Executive VP & CFO
5,000   Acquisition at $4.39 per share. 21,950
12/09/2019 Julie M. Kane
Director
2,500   Acquisition at $4.39 per share. 10,975
11/22/2019 Eric A. Rose
Director
54,501   Derivative/Non-derivative trans. at $4.92 per share. 268,144
11/22/2019 Phillip Louis Gomez
Chief Executive Officer; Director
144,028   Derivative/Non-derivative trans. at $4.92 per share. 708,617
11/22/2019 Eric A. Rose
Director
100,000   Derivative/Non-derivative trans. at $0 per share. 0
11/22/2019 Phillip Louis Gomez
Chief Executive Officer; Director
294,117   Derivative/Non-derivative trans. at $0 per share. 0
08/23/2019 Paul G. Savas
Director
10,000   Acquisition at $4.95 per share. 49,500
08/09/2019 Paul G. Savas
Director
10,000   Acquisition at $5.08 per share. 50,800
/news/latest/company/us/siga

MarketWatch News on SIGA

  1. Smallpox therapy a priority due to fears about bioterrorism: FDA

    2:23 p.m. July 13, 2018

    - Emma Court

  2. SIGA Technologies shares rise 6% on smallpox therapy approval

    2:22 p.m. July 13, 2018

    - Emma Court

  3. Preview: This Week

    12:21 p.m. April 21, 2015

    - Barron's Online

  4. Preview

    12:21 p.m. April 21, 2015

    - Barron's Online

/news/nonmarketwatch/company/us/siga

Other News on SIGA

  1. SIGA wins Health Canada approval for oral smallpox antiviral

    10:15 a.m. Dec. 1, 2021

    - Seeking Alpha

  2. SIGA extends gains amid lab incident involving smallpox vials

    8:00 a.m. Nov. 18, 2021

    - Seeking Alpha

  3. Steel City Capital Investments Q3 2021 Letter

    11:30 a.m. Oct. 26, 2021

    - Seeking Alpha

  4. 10-Q: SIGA TECHNOLOGIES INC

    4:32 p.m. Aug. 5, 2021

    - Edgar Online - (EDG = 10Q, 10K)

  5. Steel City Capital Investments Q2 2021 Letter

    11:53 a.m. July 24, 2021

    - Seeking Alpha

  6. 7 Small-Cap Biotech Stocks to Watch for Upcoming Catalysts

    2:45 p.m. May 12, 2021

    - InvestorPlace.com

  7. 10-Q: SIGA TECHNOLOGIES INC

    4:07 p.m. May 6, 2021

    - Edgar Online - (EDG = 10Q, 10K)

  8. Steel City Capital Investments Q1 2021 Letter

    12:10 p.m. May 3, 2021

    - Seeking Alpha

  9. Loading more headlines...

At a Glance

SIGA Technologies, Inc.

31 East 62nd Street

New York, New York 10065

Phone

1 2126729100

Industry

Pharmaceuticals

Sector

Health Care/Life Sciences

Fiscal Year-end

12/2021

Revenue

$124.96M

Net Income

$56.34M

2020 Sales Growth

367.3%

Employees

42.00

/news/pressrelease/company/us/siga

Press Releases on SIGA

  1. Loading more headlines...
Trending Tickers
  • /zigman2/quotes/207732364/composite MSFT-2.66%
  • /zigman2/quotes/203165245/composite T+0.53%
  • /zigman2/quotes/213120645/composite DKNG-3.54%
  • /zigman2/quotes/209901640/composite SPY-1.22%
  • /zigman2/quotes/209958550/composite AUPH+3.30%
X
Powered by StockTwits
Link to MarketWatch's Slice.